Introduction
The term 'classic' BCR/ABL-negative chronic myeloproliferative disorders (MPDs) encompasses three clonal diseases arising in a pluripotent haemopoietic stem cell that shares clinical, haematological and biological features: polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF). The recent discovery of the mutation V617F in the JAK2 gene in a high proportion of MPD patients [1] [2] [3] [4] has given biological support to the early notion by Dameshek 5 placing the three disorders within the same group. With regard to the survival, PMF is associated with a substantial reduction in life expectancy, [6] [7] [8] [9] [10] [11] [12] [13] [14] and ET affects more the patients' quality of life than their survival, whereas PV is associated with both a substantial morbidity and a certain reduction in the patients' life expectancy. [15] [16] [17] [18] Because of this, prognostic studies in the MPDs have been carried out primarily in PMF. In the last years, however, attention is increasingly being paid to the identification of prognostic factors in ET and PV, primarily focused on the risk of thrombosis. In this sense, the recent progress in the knowledge of the biology of the MPDs has stimulated the interest for establishing correlations between the disease biological features and the patients' prognosis.
The present article summarizes the current status of survival and prognosis in MPD patients, with special emphasis being made on the studies aimed at ascertaining the possible prognostic significance of the recently described biological features of these diseases. Although rare, they can occur in children. However, this sub-population is beyond the scope of this review.
Life expectancy in PMF
Primary myelofibrosis, also known as idiopathic myelofibrosis or myelofibrosis with myeloid metaplasia, is a rare disease 19, 20 usually affecting elderly people. Median survival ranges from 4 to 5.5 years in modern series [6] [7] [8] [9] [10] [11] [12] [13] [14] ( Figure 1 ). When the survival of PMF patients has been compared with that of age-and sexmatched individuals from the general population, a 31% reduction in life expectancy has been observed. 15 Although due to the increasing frequency of routine laboratory studies, there is a trend toward earlier PMF diagnosis, comparison of the survival of patients diagnosed during different time periods indicates that a possible earlier diagnosis would not translate into a longer survival. 21 Main causes of death in PMF are evolution to acute leukaemia (observed in 20% of cases at 10 years of diagnosis), infection and bleeding secondary to bone marrow failure, portal hypertension or hepatic failure secondary to hepatic/splenoportal vein thrombosis or myeloid metaplasia of the liver, thromboses in other territories and heart failure. 11, 12 With regard to young individuals with PMF, as more intensive therapeutic options for the disease are available (notably, allogeneic stem cell transplantation), there is an increasing interest for a better knowledge of their prognosis. [22] [23] [24] Thus, Morel et al. 22 observed a less aggressive course of PMF in patients younger than 55 years, as median survival of younger patients with low-risk disease according to the Lille score 11 was 13 years, which is significantly longer than the survival of lowrisk PMF patients overall. In the same sense, a survey of 121 patients 55-year old or younger from four European institutions 23 found that their prognosis was substantially better than that of the general PMF patients, with a median survival of 128 months, that is, more than twice that of the overall PMF patients. Finally, Elliott et al. 24 recently found a longer survival for PMF patients diagnosed under the age of 60 years.
Primary myelofibrosis seldom affects persons younger than 30 years. 25 It is quite likely that some early reports on such patients actually included entities other than PMF, as the blood and marrow abnormalities were often observed in the setting of infection, collagen vascular disease, renal failure, trisomy 21 or preleukaemic syndromes. 26 In a survey of 323 PMF cases collected in two European institutions, nine patients younger than 30 years were identified, representing less than 3% of the total. 25 In all cases, the disease presented without adverse prognostic factors and remained stable for years, with only two patients having died, at 10.7 and 9.9 years from diagnosis, whereas the remaining five being asymptomatic and without need for treatment. The analysis of the initial characteristics and the evolution of these very young patients showed that the majority of them had the classical form of PMF, which would have been disclosed at an early stage.
Survival of patients with post-ET myelofibrosis does not seem to differ from that of those with PMF. 27 With regard to patients with post-PV myelofibrosis, although their prognosis was claimed to be more unfavourable, 28 this has not been confirmed in a recent study. 29 
Prognostic factors and staging systems in PMF
The wide variability in the survival of PMF patients has stimulated the interest for the identification of variables for predicting survival. Table 1 summarizes the results of the main studies on prognostic factors of PMF published in the medical literature, which included more than 100 patients and were based on multivariate regression methods. To allow appropriate comparison, series including patients with the 'prefibrotic' form of PMF 32 were not considered. Among the clinical factors assessed for prognostic significance in PMF, an association between presence of hypermetabolic or constitutional symptoms (that is, fever, night sweats and weight loss) and shorter survival has been found in all studies in which it has been analysed. [10] [11] [12] 30 Age at presentation is another variable linked to the prognosis of PMF, 7,9,10,12-14 with younger subjects surviving longer. 19, 20 Although the latter statement applies to the minority of individuals 55-year old or younger at diagnosis, in patients with age over 55 years, the prognostic influence of advanced age is less clear, as at multivariate analysis, the poorer prognosis of older patients was maintained in two studies, 7, 14 but not in the majority. 9, [11] [12] [13] Male sex was associated with worse prognosis at univariate study in the Lille series, but lost significance at multivariate level. 11 The prognostic value of spleen size has been noted only occasionally, 8 and the same applies to liver size.
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The initial haemoglobin (Hb) concentration is the parameter most consistently associated with the prognosis of PMF, with the 10 g/100 ml value being the cutoff level usually determining a more unfavourable course of the disease. 7, 9, [11] [12] [13] [27] [28] [29] [30] 33 In one study, a poor prognostic influence of low reticulocyte counts was also observed. 34 Low leukocyte count was a poor prognostic indicator in the Lille and Mayo 11, 30 series, whereas high leukocyte counts had poor prognostic weight in the latter and other studies. 11, 13, 14, 28, 30, 33 According to Hb level and leukocyte count, Dupriez et al., 11 based on the analysis of the Lille series, proposed a score (the so-called Lille scoring system or Dupriez's score), which was able to identify three distinct prognostic groups. In the low-risk group (Hb 410 g/100 ml and white blood cell count o4 Â 10 9 /l or 430 Â 10 9 /l), patients had a median survival of 93 months, whereas those in the (n ¼ 137)
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Hbo10 g/100 ml /l to Hb and leukocyte count. According to the number of the latter four factors, the Mayo prognostic scoring system was able to identify three sub-populations of patients with median survivals of 134, 50 and 29 months, respectively.
The proportion of immature myeloid precursors in peripheral blood had prognostic value in two studies, 7, 9 whereas the presence (X1%) of circulating blasts in peripheral blood at presentation had a bad prognostic influence in three studies. 11, 12, 30, 35 With regard to thrombocytopaenia, it has also been associated with poorer prognosis. 13, 14, 27, 30, 36 A correlation has been observed between decreased erythropoiesis at isotopic studies and shorter survival. 7, 37 Bone marrow histologic findings did not have prognostic relevance in most studies. 12, 38, 39 A pattern of red cell aplasia in a cellular bone marrow has been associated with a more unfavourable outcome. 7 A correlation has recently been reported between PMF prognosis and angiogenesis. 40 An abnormal karyotype has been linked to shorter survival of PMF patients in two series, 13, 41 in contrast with the results from an earlier report. 42 Dupriez et al. 11 demonstrated the independent prognostic value of cytogenetic abnormalities, as this feature retained its unfavourable influence even in the low-risk PMF subgroup. Karyotypic abnormalities also had an adverse prognostic weight in the series by Reilly et al., 13 whereas they had not in the study by Tefferi et al. 43 when the abnormalities were considered as a whole. In this latter study, however, the negative influence of chromosome changes was restricted to trisomy 8 and deletion of 12p, whereas deletions of 13q and 20q did not involve shorter survival. It cannot be excluded that the lack of prognostic significance of cytogenetic abnormalities in some studies could be due to the low proportion of patients with available metaphases.
An increased number of CD34 þ cells is typically observed in the peripheral blood of patients with PMF and this parameter is also considered as a marker of the disease progression, as it has been found to be correlated with disease duration, splenomegaly size and evolution to a leukaemic phase. 44 With regard to prognosis, in two studies, a correlation was found between circulating CD34 þ cell counts and PMF risk groups, with the higher the number of such cells the more unfavourable the patient's risk group. 31, 44 Besides, a strong correlation was found between CD34 þ cell counts and the probability of acute transformation, with patients presenting with more than 300 Â 10 6 /l CD34 þ cells in blood having a 50% probability of developing acute leukaemia by 11 months from diagnosis. 44 Although the adverse prognostic influence of circulating haemopoietic progenitors was also confirmed in a study considering the number of colony-forming units granulocyte-macrophage and erythroid burst-forming units in peripheral blood, 31 such prognostic correlation could not be demonstrated in other study. 45 In individuals with PMF and younger than 55 years, the factors associated with poor prognosis are anaemia (Hb value o10 g/100 ml), constitutional symptoms and presence of blast cells in peripheral blood. 23 It is worth noting that in these younger patients, no association was found between presence of cytogenetic abnormalities and survival, although only 17% of them displayed such a finding. 23 On the basis of the abovementioned three variables, two prognostic groups could be clearly identified: a 'low-risk' group, including patients with none or one of the bad prognostic factors, and a 'high-risk' group, integrated by patients with two or three unfavourable factors. The 'low-risk' group encompassed three quarters of the overall patients and its median survival approached 15 years, whereas the 'high-risk' group included a quarter of the patients, with a median survival of less than 3 years. This prognostic scoring system is of help at the time of making treatment decisions in young patients with PMF. More recently, the Mayo Clinic group has proposed a staging system for PMF patients below the age of 60 years. On the basis of Hbp10 g/100 ml, leukocyte counts o4 Â 10 9 /l or 430 Â 10 9 /l, platelets o100 Â 10 9 /l and monocytes 41 Â 10 9 /l, three prognostic groups were identified, with the median survival being around 14 years for the low-risk group of patients and 2 years for the high-risk group. 24 Prognostic factors for acute transformation of PMF include severe anaemia, a high proportion of immature myeloid cells in blood and a high number of circulating CD34 þ cells. 44 In one series, an increased risk of acute leukaemia was registered in patients submitted to splenectomy, 46 but this was not confirmed in a study from the Mayo Clinic. 47 
Life expectancy in polycythaemia vera and essential thrombocythaemia
Life expectancy is the main concern of patients with PV and ET at diagnosis of the disease, but the studies on this issue are relatively scarce. [15] [16] [17] [18] 20, 48, 49 A study on 831 patients with PV and ET followed for a median time of about 10 years provided evidence that life expectancy of PV patients is reduced when compared with that of the general population, whereas the survival of patients with ET is not significantly shortened. 18 A study from Mayo Clinic including 322 patients with ET followed for a median time of 13.6 years confirmed these data on survival in the first decade of disease and showed that survival became significantly worse thereafter. 50 In the Pavia study, the standardized mortality ratio, which is the ratio of the observed number of deaths in the patients' population to the number of deaths expected in the reference population, was 1.6 in PV and 1.0 in ET, 18 which means that PV patients have a 1.6-fold higher mortality than the general population whereas ET patients do not have an increased mortality. When the standardized mortality ratio was analysed according to the patient's age at diagnosis, mortality was 3.3-fold higher in PV patients younger than 50 years and 1.6-fold higher in those over 50 years, whereas it was not increased in ET patients from each age category with regard to the reference population. ET is therefore the more indolent of the MPDs and young patients with PV would accumulate timedependent disease-related complications. Similar conclusions have been obtained in the few additional studies focused on the outcome of young patients with PV and ET. [51] [52] [53] [54] [55] [56] [57] The World Health Organization classification, 58 published in 2001, recognized a new entity within the MPDs, the so-called 'prefibrotic' stage of PMF, 32 which would include patients who would have been classified as having ET using the Polycythemia Vera Study Group criteria. 58 Although it has been claimed that patients with 'prefibrotic' PMF had a loss in life expectancy when compared to those with ET, 59 no differences in clinical outcome were observed in a recent study focused on the pathological and clinical distinction between ET and 'prefibrotic' PMF. 60 Moreover, from the biological point of view, neither circulating CD34 þ cell count, as an expression of stem-cell mobilization, nor granulocyte JAK2 (V617F) allele burden differs between the two conditions. 61 The recently proposed revision of the World Health Organization classification for chronic MPDs 62 allows to diagnose this condition only if the typical histopathological findings are present with, at least, two of the following criteria: leukoerythroblastosis, increase in serum lactate dehydrogenase level, anaemia, and palpable splenomegaly.
Life expectancy of patients with PV or ET is mainly affected by disease-related complications, such as vascular disease (thrombosis and haemorrhage) and transformation to either myelofibrosis or leukaemia. The incidence of disease-related complications varies significantly between the two diseases. Indeed, PV patients would have a higher incidence of thrombosis and evolution to myelofibrosis and leukaemia than ET patients. 18 Conversely, the incidence of solid cancers does not differ between the two conditions, indicating that disease and disease-specific treatments do not directly influence the occurrence of extrahaematological malignancies. In PV, the incidence of thrombosis was 18 per 1000 person-years, being about 5 per 1000 person-years for myelofibrosis and leukaemia, whereas in ET, the incidence of thrombosis was 12 per 1000 person-years, being 1.6 per 1000 person-years for myelofibrosis and 1.2 per 1000 person-years for leukaemia. The results of the European Collaboration on Low-dose Aspirin in Polycythemia Vera study 63 showed that cardiovascular mortality in PV patients accounted for 45% of all deaths, whereas haematologic transformation was the cause of death in 13% of cases. Therefore, given that thrombosis is, by far, the most frequent complication of PV and ET, there is a clear rationale for stratifying patients at diagnosis according to their thrombosis risk.
A recently arisen issue in the MPDs concerns familial cases of these diseases. By an interview-based investigation of family history, a study on 458 patients with apparently sporadic MPD 64 showed that the prevalence of familial MPD is 7.6% (18 of 206 with PV, 10 of 167 with ET and 7 of 85 with PMF). The clinical presentation of patients with familial and sporadic MPDs was not statistically different. Familial cases had vascular complications and evolution to myelofibrosis and leukaemia as it happens in sporadic cases. The 10-year survival was 83% for patients with familial PV, 100% for those with familial ET and 30% for those with familial PMF.
Prognostic factors in polycythaemia vera and essential thrombocythaemia
Age at diagnosis and a previous history of thrombosis are the two most important prognostic factors for thrombosis in PV and ET 65 and represent the state of the art for risk stratification in treatment decision making for these patients ( Table 2) . The relationship of age at presentation and prior history of thrombosis with the subsequent risk of thrombosis has been demonstrated in several large studies in both PV 16, 63, 66, 67 and ET. [68] [69] [70] Thus, patients with the two risk factors at diagnosis are considered at high risk for thrombosis, whereas those with none of them are considered at low risk and require a different treatment approach.
No evidence is available for the link between the initial platelet count and the risk of subsequent thrombosis in either PV or ET. 70, 71 Additional information on the subject has been derived from clinical trials in ET patients at high risk of thrombosis. In a prospective trial using hydroxyurea, a reduction in both platelet count and rate of thrombosis was shown. 72 Subsequently, in a prospective randomized trial of anagrelide plus aspirin vs hydroxyurea plus aspirin, anagrelide (a selective platelet-lowering agent) failed to demonstrate an advantage with respect to hydroxyurea in reducing the arterial thrombosis and major haemorrhage, despite an equivalent long-term control of the platelet counts. 73 By pooling these data, the benefit of cytoreductive therapy in decreasing the thrombosis rate would be rather due to its overall myelosuppressive effect than due to a selective platelet count reduction. On the other hand, there is a more evident correlation between extreme thrombocytosis and bleeding risk, which would be attributed to an acquired von Willebrand disease. 74 Therefore, in treatment decision making, platelet counts over 1500 Â 10 9 /l should be considered as a risk factor for haemorrhage.
Increased leukocyte count has been identified as an independent risk factor for thrombosis in both PV and ET. 17, 50, [75] [76] [77] In the ECLAP study on PV, patients with a leukocyte count exceeding 15 Â 10 9 /l had a significant increase in the risk of myocardial infarction as compared with those with leukocyte counts below 10 Â 10 9 /l. 75 In ET, a significant correlation has been found between the initial leukocyte count and the subsequent risk of thrombosis in two studies. In both, a cutoff value for the leukocyte count was identified, being 15 Â 10 9 /l in a study including 322 patients 50 and 8.7 Â 10 9 /l in other study analysing 439 patients. 76 However, no correlation between initial leukocyte count and subsequent thrombosis was observed in a study from the Mayo Clinic including 605 ET patients. 77 Therefore, for the time being, the burden of evidence would not be sufficient to consider leukocyte count as a risk factor at time of treatment decision making, given the fact that the relationship between the initial leukocyte count and the subsequent thrombosis may be affected by treatment. From a functional point of view, a role for leukocytes, platelets and leukocyteplatelet aggregates as cooperating mechanisms for the thrombosis in PV and ET has been shown. Thus, their activation, [78] [79] [80] as well as the correlation with the JAK2 mutational status might be more important than the number of leukocytes per se. In this sense, a correlation has also been found recently between the JAK2 status and haemostasis activation parameters, 80 leukocyte activation (by means of leukocyte alkaline phosphatase) 61 and platelet activation. 81 
Table 2
Initial risk factors in patients with polycythaemia vera and essential thrombocythaemia according to their current role in treatment decision making 
SPOTLIGHT
Several studies have been published on the possible contribution of well-defined cardiovascular risk factors, such as arterial hypertension, smoking habit, hypercholesterolaemia and diabetes mellitus, to the risk of thrombosis, but the results have been conflicting. 50, 55, 70, 72, [82] [83] [84] Taking into account that these cardiovascular risk factors may have additional influence on the expected risk of thrombosis in PV and ET, patients with such risk factors are usually considered to belong to an intermediate-risk category. 85, 86 Nevertheless, the use of cytoreductive treatment is not recommended in these patients, but an appropriate management of the reversible risk factors is mandatory.
As the incidence of leukaemia is low and this complication occurs late in the evolution of PV and ET, large-and long-term studies are required to identify the risk factors at diagnosis for developing such a complication. A French study showed that the incidence of leukaemia did not reach a plateau over time. 87 In some studies, patient's age influenced the risk of leukaemia in PV, 65, 87 whereas leukocyte count did in both ET and PV. 17, 88 No clear association has been demonstrated between leukaemia and a specific drug exposure history, 18, 87, 89 with the exception of 32 P and chlorambucil, 67 whereas the use of more than one cytoreductive therapy clearly increased the risk of leukaemia. 18, 67 In PV, the ECLAP study failed to show significant differences in terms of leukaemic evolution between patients treated with hydroxyurea and those managed with phlebotomy only. 90 In addition, a study from Pavia demonstrated that patients with PV and ET treated with hydroxyurea or pipobroman alone had a similar risk of developing leukaemia, 18 as previously reported in the randomized French study of PV patients. 91 Recently, no correlation between specific treatment and the occurrence of leukaemia in ET was observed in a study from the Mayo Clinic, whereas a leukocyte count exceeding 15 Â 10 9 /l was the more relevant adverse prognostic factor. 88 Concerning the evolution of PV to myelofibrosis, a recent study identified that patients with a leukocyte count 415 Â 10 9 /l at PV diagnosis had a higher risk of developing post-PV myelofibrosis than patients with a lower count. 29 In addition, it was found that the longer the duration of PV, the higher the risk of developing myelofibrosis, as it had been reported in a previous study. 63 Two circumstances may expose patients with PV and ET to an increased morbidity: surgery and pregnancy, the latter mainly affecting young women with ET. In a recent retrospective study reporting the outcome of 311 surgical interventions in 105 patients with PV and 150 with ET, 7.7% of them were complicated by fatal arterial or venous thrombosis and 7.3% by fatal major haemorrhage within 3 months from the procedure. 92 However, no prognostic factors were identified that could predict post-surgery outcome. With regard to pregnancy, in a recent study on 103 pregnancies in 62 women with ET, 92 the rate of live birth was 64%, with 51% of pregnancies being uneventful. Maternal complications were registered in 9% of cases and fetal complications occurred in 40% of them. The pregnancy outcome was independent from that of a previous pregnancy and fetal loss was 3.4-fold higher than that of the general population. Multivariate study identified the JAK2 V617F mutation as an independent predictor of pregnancy complications, as patients carrying the mutation had an odds ratio of 2.02 to develop complications as compared with those with wild-type JAK2. Data from the literature on the outcome of pregnancy in patients with PV and PMF are scarce. Patients with PV seem to have a similar rate of fetal complications but a higher rate of maternal complications than patients with ET. 93 
Prognostic implications of the JAK2 V617F mutation in the MPDs
It is now estimated that 95% of PV and 50-60% of ET and PMF patients carry an acquired point mutation in the pseudokinase domain of the Janus kinase-2 conferring constitutive tyrosine kinase activity. [1] [2] [3] [4] Following the discovery of such molecular abnormality, considerable interest has arisen on its possible prognostic value.
As thrombosis represents the initial presentation event for 12-39% of patients with ET and PV, and still more will suffer a thrombotic complication following diagnosis, 68 the predictive value of the V617F mutation on the risk of thrombosis has been investigated. As a matter of fact, although risk stratification based on clinical parameters is an important cornerstone guiding the treatment of patients with MPDs, a better molecular understanding of these diseases may improve our ability to identify those patients destined to develop thrombosis.
Soon after the description of the JAK2 V617F mutation, two retrospective analyses of 50 and 60 patients each with ET found that those with the mutation were more likely to have suffered from thrombosis 94, 95 (Table 3) . Besides, post hoc genetic analysis of the high-risk ET cohort in the Medical Research Council Primary Thrombocythemia-1 study demonstrated that the mutation was associated with higher Hb and white blood counts and that such patients had higher rates of venous thromboses. 97 In a more recent study of 179 ET patients, the frequency of thrombosis in JAK2 mutants was significantly increased (33 vs 17%) and comparable to that of PV patients. 98 However, three other retrospective concurrent studies with more than 100 patients each 50, 76, 96 reported that the mutation was not associated with the incidence of thrombohaemorrhagic events. These differences may reflect the inadequacy of clinical criteria for distinguishing ET from PV, different patient selection and study design, and reliance solely on qualitative JAK2 V617F expression and not on quantitative allele burden measure.
As the complete loss of normal JAK2 allele is expected to have profound effects on cell phenotype, a high load of allele burden may be hypothesized to have an influence on prognosis. About 25-30% of PV patients and 2-4% of patients with ET harbour the mutation in the so-called homozygous state, a condition in which at least 51% of JAK2 alleles in the granulocytes are mutated as a result of the mitotic recombination process. In a multicentre retrospective study including ET and PV patients, thrombotic events were significantly more frequent in homozygous patients with ET than in wild-type or heterozygous patients (hazard risk, 3.97; 95% CI, 1.34-11.7). 103 Employing quantitative assays for V617F allele, two retrospective series of ET patients demonstrated that JAK2 mutation and its allele burden were associated with thrombosis. 101, 102 Although one series provided evidence that only venous thrombosis occurring during follow-up was correlated with allele burden, 103 the other showed that only arterial thrombosis at diagnosis proved associated with allele burden. 102 Moreover, discrepant results continued also with quantitative analysis reports (Table 3) . 99 Given the extremely high incidence of the JAK2 mutation in PV, the utility of the presence of the mutated allele itself is not likely to be in the prognostic arena in this disease. However, in a multicentre retrospective study including ET and PV patients (118 JAK2 V617F homozygous, 587 heterozygous and 257 wildtype), no significant differences were observed in the overall rate and the type of major thrombosis between heterozygous and homozygous PV patients. 103 Similar findings have been reported in a smaller series by Tefferi et al.
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SPOTLIGHT
Employing quantitative assays for V617F allele in a prospective series of PV patients who were genotyped at diagnosis, patients with cardiovascular events (either at diagnosis or during follow-up) progressively increased from 10, 14, 24 to 37% in the different groups according to categorized JAK2 V617F allele burden (P ¼ 0.001 using the w 2 test for trend). 100 Accordingly, the risk ratio of total thrombosis was 3.56-fold higher (95% CI, 1.47-7.1) in patients with greater than 75% mutant allele when compared to a reference population (P ¼ 0.004). Mutant allele burden did not impact on thrombosis at time of diagnosis, but the risk ratio of thrombosis during follow-up was significantly increased in patients with more than 75% mutant allele (risk ratio, 7.1; 95% CI, 1.6-10.1). At univariate analysis, the factors associated with thrombosis were age, a previous history of thrombosis, leukocytosis and mutant allele burden, but at multivariate study, the only variable that maintained a significant association with the development of cardiovascular events was the JAK2 V617F allele burden (P ¼ 0.039). Recently, partially conflicting results have been reported by Tefferi et al. 105 However, the retrospective nature of this study, as well as the fact that bone marrow cells rather than purified granulocytes were used for V617F allele quantification, precludes an adequate comparison of the results.
In summary, findings of large studies indicate that identification of the JAK2 V617F mutation might be a prognostic marker for thrombosis in ET. More important, accurate determination of JAK2 V617F allele burden using quantitative assay, rather than merely defining heterozygosity vs homozygosity, seems to be critical for the assessment of the prognostic role of JAK2 V617F allele in ET and PV. In this sense, the category of patients having greater than 75% mutant allele would be characterized by a significantly increased risk of developing major cardiovascular events during follow-up.
The mechanistic role played by the JAK2 mutation in the development of the thrombosis is not clearly elucidated. JAK2 V617F has been associated with higher leukocyte counts 80, 81, 95 and neutrophil activation, whereas neutrophil/platelet complexes have been implicated in the thrombosis of the MPDs. [79] [80] [81] 106 Older age, higher Hb level and higher leukocyte count displayed by V617F-mutated patients might represent confounding factors in the association of mutant genotype with thrombosis, particularly in homozygous ET patients with higher rate of thrombosis. In ET and PV, the independent predictive role of JAK2 mutant allele burden was maintained after elimination of potential confounders at multivariate analysis, in which wellestablished risk factors for thrombosis, such as age, previous thrombosis and leukocytosis, were included. [101] [102] [103] Should these findings be further corroborated in prospective trials involving a consistent number of homozygous patients, it could be suggested that high V617F allele burden in ET and PV might represent a novel risk factor for thrombosis in addition to age, previous thrombosis and leukocytosis.
Besides thrombosis, transformation to myelofibrosis is the major cause of morbidity and mortality in PV and ET. The influence of JAK2 V617F mutation in the progression of the MPD may be hypothesized from mouse modelling. Transplantation experiments have shown the development of many key features associated with PV, including leukocytosis, splenomegaly due to extramedullary haematopoiesis and late development of myelofibrosis. 107 The mouse model is compatible with the hypothesis in which overexpression of JAK2 V617F induces a myeloproliferative disease that progresses to a PMF-like disease. Several studies have documented that in PV, myelofibrosis transformation occurred more frequently in homozygous than in heterozygous patients. Thus, the rate of fibrotic transformation was 11.5 vs 1.4%, respectively, in the study of Vannucchi et al., 100 and 23 vs 2% in the one by Tefferi et al. 105 Similar results were obtained in ET, 100 with 14.3% of homozygous patients developing myelofibrosis as compared to 1.6% of wildtype patients and 4.7 of the heterozygous counterparts.
Few studies have directly evaluated the prognostic relevance of JAK2 V617F in PMF. 108, 109 Patients with the mutation had higher leukocyte counts and a history of thrombosis or pruritus and were less likely to require transfusion during follow-up. Table 3 The value of JAK2 V617F mutation on the risk of thrombosis in ET 
Divergent results were obtained with regard to the impact of the JAK2 mutation on both survival 108, 109 and evolution to acute leukaemia. [110] [111] [112] [113] However, the relatively small size of the cohorts hampered a precise dissection of genotype-phenotype associations, whereas the retrospective design of the studies reduced the strength of the evidence. In a longitudinal prospective study, Barosi et al. 113 determined the progression rate to clinically relevant outcomes in 174 patients with JAK2 mutation determined at diagnosis, with the mutation being identified in 63.4% of cases. None of the V617F-negative patients sequentially genotyped progressed to V617F positivity, whereas the progression rate from the heterozygous to the homozygous mutation was 10 per 100 patient-years. The JAK2 mutation predicted the evolution toward large splenomegaly, need of splenectomy and leukaemic transformation. The strongest influence of the mutated genotype was exerted on the risk of leukaemic transformation, which was 5.2 times higher in non-mutated patients. The risk remained significant after adjustment for age, sex, Dupriez's risk score, leukocyte count and percentage of blasts in peripheral blood, the known main risk factors for leukaemic transformation in PMF. In conclusion, JAK2 mutation might represent the first biological prognostic marker of PMF independent of conventional predictors. However, this should be confirmed by additional studies.
Conclusion
The prognosis of PMF patients mainly relies on the degree of anaemia at diagnosis. Although it is quite likely that this parameter will remain the basic tool for predicting the patients' outcome, international collaborative efforts are currently in progress to help refining the prognostic assessment of this disease. With regard to PV and ET, the prognostic parameters currently considered for the patients' clinical management are age 460 years, history of thrombosis or bleeding and platelet count 41500 Â 10 9 /l, as they have a proven value to distinguish patients with low or high risk of vascular complications. However, in the setting of future prospective clinical trials, other factors that should be tested for prognostic influence include leukocyte count, JAK2 (V617F) mutational status and mutational allele burden.
